Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 8/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7466776 | 0.87 | GSTP1 (0.42) | PTGER1PTGER4PTGER3PTGER2SMN1; SMN2 | |
| SCHEMBL4288181 | 0.83 | HSD17B1 (0.38) | CYP2C9HSD17B1HSD17B2 | |
| SCHEMBL4282286 | 0.80 | MAOB (0.44) | PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL4279106 | 0.80 | HSD17B1 (0.39) | CYP2C9CYP1A2CYP2C19ADORA1HSD17B1 | |
| SCHEMBL4275974 | 0.80 | HSD17B1 (0.36) | CYP2C9HSD17B1HSD17B2 | |
| SCHEMBL4276950 | 0.80 | HSD17B1 (0.38) | CYP2C9HSD17B1HSD17B2 | |
| SCHEMBL7471019 | 0.80 | MAOB (0.47) | PTGER1SMN1; SMN2RAB9AMAPTNPSR1 | |
| SCHEMBL7470974 | 0.80 | PLA2G1B (0.44) | PTGER1CYP2C9KDM4E | |
| SCHEMBL7460118 | 0.80 | MAOB (0.43) | LMNAPTGS1PTGS2 | |
| SCHEMBL4288061 | 0.78 | CHRM3 (0.38) | CYP2C9HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397462-A2 | Compounds, compositions and methods of treatment for heart failure | Cytokinetics, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060241110-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-10-26 | — | — | US | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241110-A1 | Compounds, compositions, and methods | TNNI3, TNNT2, TNNC1 | PTGER1 3447/4885PTGER4 3707/4885PTGER3 3255/4885 |
| US-20050159416-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | PTGER1 3459/4885PTGER4 3696/4885PTGER3 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.